IASO Bio Presents Clinical Data and Single-Cell Multi-Omics Analysis of Eque-cel (Idecabtagene Autoleucel) for CNS Autoimmune Diseases at EAN 2024
IASO Biotechnology
Cancer Treatment New Drug Developer
July 1, 2024, Nanjing, Shanghai, China, and San Jose, California – IASO Bio, a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative cell therapies, delivered an oral presentation at the 2024 European Academy of Neurology (EAN) Annual Meeting.Clinical Data and Single-Cell Multi-Omics Analysis Results of IASO Bio's Fully Human BCMA-Targeted Chimeric Antigen Receptor Autologous T-Cell Injection (Equecabtagene Autoleucel) for the Treatment of Central Nervous System Immune Diseases。
Professor Qin Chuan from Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOral Presentation at the EAN Annual Meeting
Report Title：BCMA CAR-T Cell Therapy and Single-Cell Analysis for Autoimmune Diseases of the Central Nervous System
Report Type：Oral Report
Report Time：July 1, 2024, 8:30 AM - 9:45 AM (EEST)
Reporting Location：Helsinki, Finland
Abstract Number：A-24-12777
Reporter：Professor Qin Chuan from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
This report is based on the results of an investigator-initiated exploratory clinical study (NCT04561557) evaluating the safety and efficacy of infusing Icaritin Cell Injection for the treatment of relapsed/refractory antibody-mediated idiopathic inflammatory neurological diseases. The study is being conducted at Tongji Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology, by a research team led by Professor Wei Wang from the Department of Neurology at Tongji Hospital.
The study enrolled 12 subjects with aquaporin-4 (AQP4) antibody-positive relapsing/refractory neuromyelitis optica spectrum disorder (NMOSD). The enrolled subjects were patients who had been treated with at least one immunosuppressant for more than a year but had poor symptom control. The results showed that the Icarus injection demonstrated good tolerability and safety, persistent clearance of pathogenic antibodies, and potential clinical efficacy in NMOSD. CAR-T cells with chemotactic properties can penetrate the blood-brain barrier into the central nervous system, directly killing abnormal plasma cells, reducing the secretion of intrathecal autoantibodies and the abnormal activation of immune cells, thereby correcting the immunological disorder in the central nervous system of NMOSD patients, which is beneficial for the central immune reconstruction of patients.
Tongji Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology and IASO Bio, as one of the world's first research teams to use BCMA CAR-T in the treatment of immune diseases, have validated the clinical value of innovative cell therapy for relapsed and refractory immune diseases with their groundbreaking research results. This has increasingly gained recognition and attention internationally. Currently,BCMA CAR-T therapy has been evaluated by the International Neuromyelitis Optica Study Group (NEMOS) as one of the most promising treatment strategies and included in the latest revised treatment recommendations (J Neurol 2024).Maximilian F. Konig, a professor in the Department of Immunology at Johns Hopkins University, pointed out in his review of the year’s advances in cell therapy for the journal *Nat Rev Rheumatol* (Year in review: Immunotherapies in 2023: The rise of precision cellular therapies) that,The application of CAR-T therapy has brought epoch-making progress to innovative cell treatment for immune diseases.。
The principal investigator of this clinical study, Professor Wang Wei from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology"This study is the world's first clinical trial of CAR-T therapy in the field of AQP4-mediated relapsing/refractory NMOSD, not only demonstrating the encouraging efficacy and controllable safety of Icaritamab Injection in NMOSD but also elucidating the cellular kinetics and immunological characteristics of CAR-T therapy for central nervous system autoimmune diseases. It provides a new therapeutic approach for antibody-mediated autoimmune diseases and offers important scientific evidence for subsequent product iteration and improvement of CAR-T cell therapy for immune disorders. In addition to NMOSD, Icaritamab Injection has shown excellent clinical efficacy in treating other antibody-mediated autoimmune diseases, including myasthenia gravis and immune-mediated necrotizing myopathy, even reversing disease symptoms, with multiple related research papers published in authoritative international academic journals. The patient population with autoimmune diseases is vast, with recurring episodes that are difficult to cure, requiring long-term or even lifelong medication, representing a significant unmet clinical need. We will continue to explore the application of Icaritamab Injection in more refractory autoimmune diseases with the IASO Bio team to transform the treatment landscape of autoimmune diseases."
”
About IASO Bio
